Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663313 | 0.93 | KDM4E (0.58) | KDM4EALDH1A1MAPTHPGDLMNA | |
| SCHEMBL85946 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1MAPTHPGDCYP3A4 | |
| SCHEMBL12793494 | 0.85 | HTT (0.56) | KDM4EALDH1A1MAPTHPGDLMNA | |
| Hydrochloric Acid SCHEMBL5012089 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1MAPTHPGDCYP3A4 | |
| SCHEMBL29191828 | 0.84 | LCK (0.57) | KDM4EALDH1A1MAPTHPGDLMNA | |
| SCHEMBL856225 | 0.84 | GAA (0.58) | KDM4EALDH1A1HPGDLMNACYP3A4 | |
| SCHEMBL1015430 | 0.84 | KDM4E (0.77) | KDM4EALDH1A1MAPTHPGDLMNA | |
| SCHEMBL29918211 | 0.84 | GAA (0.58) | KDM4EALDH1A1HPGDLMNACYP3A4 | |
| Nitrogen SCHEMBL28644623 | 0.83 | KDM4E (0.65) | KDM4EALDH1A1MAPTHPGDCYP3A4 | |
| SCHEMBL3836141 | 0.82 | MAPT (0.64) | KDM4EALDH1A1MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-110590683-A | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-115322158-B | As KRASG12CSubstituted quinazoline compounds of protein inhibitor | 江南大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| WO-2023287730-A1 | TRICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-115322158-A | As KRAS G12C Substituted quinazoline compounds of protein inhibitor | 江南大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-1641767-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | Boehringer Ingelheim International GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108664-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0449557-B1 | Recovery of values from cereal wastes | CA MINISTER AGRICULTURE & FOOD (CA) | 1996-09-04 | — | — | EP | disclosed |
| US-5169660-A | Steeping cereals in water to liquify endosperm, then macerating them in aqueous ethanol solution, separation and recovery of bran and endosperm materials | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE (CA) | 1992-12-08 | — | — | US | disclosed |
| EP-0449557-A2 | Recovery of values from cereal wastes | Her Majesty in Right of Canada as represented by the Minister of Agriculture Canada (CA) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | KDM4E 3496/4885ALDH1A1 1923/4885MAPT 910/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | KDM4E 1254/4885ALDH1A1 4031/4885MAPT 1456/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | KDM4E 2024/4885ALDH1A1 1873/4885MAPT 2435/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | KDM4E 4489/4885ALDH1A1 4357/4885MAPT 4820/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | KDM4E 1437/4885ALDH1A1 1079/4885MAPT 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.